BOEHRINGER INGELHEIM Company Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the competitive landscape for BOEHRINGER INGELHEIM, and what generic alternatives to BOEHRINGER INGELHEIM drugs are available?
BOEHRINGER INGELHEIM has forty-eight approved drugs.
There are seventy-five US patents protecting BOEHRINGER INGELHEIM drugs. There is one tentative approval on BOEHRINGER INGELHEIM drugs.
There are two thousand one hundred and seventy-three patent family members on BOEHRINGER INGELHEIM drugs in sixty-four countries and two hundred and twenty-six supplementary protection certificates in nineteen countries.
Summary for BOEHRINGER INGELHEIM
| International Patents: | 2173 |
| US Patents: | 75 |
| Tradenames: | 37 |
| Ingredients: | 29 |
| NDAs: | 48 |
| Patent Litigation for BOEHRINGER INGELHEIM: | See patent lawsuits for BOEHRINGER INGELHEIM |
| PTAB Cases with BOEHRINGER INGELHEIM as petitioner: | See PTAB cases with BOEHRINGER INGELHEIM as petitioner |
Drugs and US Patents for BOEHRINGER INGELHEIM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim | TRADJENTA | linagliptin | TABLET;ORAL | 201280-001 | May 2, 2011 | AB | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | ||||
| Boehringer Ingelheim | MIRAPEX ER | pramipexole dihydrochloride | TABLET, EXTENDED RELEASE;ORAL | 022421-007 | Jun 17, 2011 | AB | RX | Yes | No | 7,695,734 | See Plans and Pricing | Y | See Plans and Pricing | ||
| Boehringer Ingelheim | SYNJARDY | empagliflozin; metformin hydrochloride | TABLET;ORAL | 206111-002 | Aug 26, 2015 | AB | RX | Yes | No | 7,713,938 | See Plans and Pricing | Y | Y | See Plans and Pricing | |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for BOEHRINGER INGELHEIM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim | SPIRIVA RESPIMAT | tiotropium bromide | SPRAY, METERED;INHALATION | 021936-002 | Sep 15, 2015 | 6,846,413*PED | See Plans and Pricing |
| Boehringer Ingelheim | MICARDIS HCT | hydrochlorothiazide; telmisartan | TABLET;ORAL | 021162-001 | Nov 17, 2000 | 5,591,762 | See Plans and Pricing |
| Boehringer Ingelheim | STIOLTO RESPIMAT | olodaterol hydrochloride; tiotropium bromide | SPRAY, METERED;INHALATION | 206756-001 | May 21, 2015 | 7,104,470 | See Plans and Pricing |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for BOEHRINGER INGELHEIM drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-releaseTablets | 2.5 mg/1000 mg 5 mg/1000 mg | ➤ Subscribe | 2018-03-28 |
| ➤ Subscribe | Tablets | 5 mg | ➤ Subscribe | 2015-05-04 |
| ➤ Subscribe | Extended-release Tablets | 2.25 mg and 3.75 mg | ➤ Subscribe | 2011-07-26 |
| ➤ Subscribe | Extended-release Tablets | 400 mg | ➤ Subscribe | 2013-06-21 |
| ➤ Subscribe | Tablets | 10 mg/5 mg and 25 mg/5 mg | ➤ Subscribe | 2018-08-01 |
| ➤ Subscribe | Tablets | 2.5 mg/500 mg, 2.5 mg/850 mg, 2.5 mg/1000 mg | ➤ Subscribe | 2015-05-04 |
| ➤ Subscribe | Tablets | 80 mg/12.5 mg and 40 mg/12.5 mg | ➤ Subscribe | 2008-12-31 |
| ➤ Subscribe | Extended-release Capsules | 25 mg and 200 mg | ➤ Subscribe | 2007-02-01 |
| ➤ Subscribe | Tablets | 0.125 mg, 0.5 mg, 1 mg and 1.5 mg | ➤ Subscribe | 2005-06-24 |
| ➤ Subscribe | Capsules | eq. to 75 mg base and 150 mg base | ➤ Subscribe | 2014-10-20 |
| ➤ Subscribe | Tablets | 0.75 mg | ➤ Subscribe | 2008-07-31 |
| ➤ Subscribe | Inhalation Powder Capsules | 18 mcg | ➤ Subscribe | 2018-05-11 |
| ➤ Subscribe | Tablets | 5 mg/500 mg5 mg/1000 mg12.5 mg/500 mg12.5 mg/1000 mg | ➤ Subscribe | 2018-08-01 |
| ➤ Subscribe | Extended-release Tablets | 0.375 mg, 0.75 mg, 1.5 mg, 3 mg and 4.5 mg | ➤ Subscribe | 2010-06-01 |
| ➤ Subscribe | Extended-release Tablets | 5 mg/1000 mg10 mg/1000 mg12.5 mg/1000 mg25 mg/1000 mg | ➤ Subscribe | 2018-08-01 |
| ➤ Subscribe | Tablets | 20 mg, 30 mg and 40 mg | ➤ Subscribe | 2017-07-12 |
| ➤ Subscribe | Tablets | 10 mg and 25 mg | ➤ Subscribe | 2018-08-01 |
| ➤ Subscribe | Tablets | 20 mg, 40 mg and 80 mg | ➤ Subscribe | 2006-12-26 |
| ➤ Subscribe | Tablets | 80 mg/25 mg | ➤ Subscribe | 2009-02-27 |
| ➤ Subscribe | Capsules | 100 mg and 150 mg | ➤ Subscribe | 2018-10-15 |
| ➤ Subscribe | Tablets | 0.25 mg | ➤ Subscribe | 2005-05-27 |
| ➤ Subscribe | Capsules | eq. to 110 mg base | ➤ Subscribe | 2015-12-15 |
| ➤ Subscribe | Oral Suspension | 7.5 mg/5 mL | ➤ Subscribe | 2009-12-17 |
International Patents for BOEHRINGER INGELHEIM Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Slovenia | 1224170 | See Plans and Pricing |
| European Patent Office | 1948179 | See Plans and Pricing |
| Indonesia | 21341 | See Plans and Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for BOEHRINGER INGELHEIM Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2525812 | C201730027 | Spain | See Plans and Pricing | PRODUCT NAME: IDARUCIZUMAB; NATIONAL AUTHORISATION NUMBER: EU/1/15/1056; DATE OF AUTHORISATION: 20151120; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/15/1056; DATE OF FIRST AUTHORISATION IN EEA: 20151120 |
| 0418716 | 0290010-8 | Sweden | See Plans and Pricing | PRODUCT NAME: TIOTROPIUM, 3BETA-(DI(2-TIENYL)HYDROXIACETOXI)-6BETA,7BETA-EPO XI-8METYL-1ALFAH,5ALFAH-TROPANIUM, ELLER ETT SALT DAERAV; NAT. REGISRTATION NO/DATE: 18094 20020503; FIRST REGISTRATION: NL RVG 26 191 20011009 |
| 2525812 | CR 2017 00031 | Denmark | See Plans and Pricing | PRODUCT NAME: IDARUCIZUMAB; REG. NO/DATE: EU/1/15/1056 20151124 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
